journal
Journals Metabolism: Clinical and Exper...

Metabolism: Clinical and Experimental

https://read.qxmd.com/read/38729601/cgas-suppresses-%C3%AE-cell-proliferation-by-a-sting-independent-but-cebp%C3%AE-dependent-mechanism
#21
JOURNAL ARTICLE
Zixin Cai, Yan Yang, Jiaxin Zhong, Yujiao Ji, Ting Li, Jing Luo, Shanbiao Hu, Hairong Luo, Yan Wu, Feng Liu, Jingjing Zhang
AIMS/HYPOTHESIS: cGAS (cyclic GMP-AMP synthase) has been implicated in various cellular processes, but its role in β-cell proliferation and diabetes is not fully understood. This study investigates the impact of cGAS on β-cell proliferation, particularly in the context of diabetes. METHODS: Utilizing mouse models, including cGAS and STING (stimulator of interferon genes) knockout mice, we explored the role of cGAS in β-cell function. This involved β-cell-specific cGAS knockout (cGASβKO ) mice, created by breeding cGAS floxed mice with transgenic mice expressing Cre recombinase under the insulin II promoter...
May 8, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38729600/the-evolutionary-conserved-mir-137-325-tandem-mediates-obesity-induced-hypogonadism-and-metabolic-comorbidities-by-repressing-hypothalamic-kisspeptin
#22
JOURNAL ARTICLE
María S Avendaño, Cecilia Perdices-Lopez, Yolanda Guerrero-Ruiz, Francisco Ruiz-Pino, Ana B Rodriguez-Sanchez, María J Sanchez-Tapia, Verónica Sobrino, Rafael Pineda, Alexia Barroso, Alejandro Correa-Sáez, Maribel Lara-Chica, José C Fernandez-Garcia, Ana B García-Redondo, Raquel Hernanz, Miguel Ruiz-Cruz, David Garcia-Galiano, Nelly Pitteloud, Marco A Calzado, Ana M Briones, María J Vázquez, Manuel Tena-Sempere
BACKGROUND: Obesity-induced hypogonadism (OIH) is a prevalent, but often neglected condition in men, which aggravates the metabolic complications of overweight. While hypothalamic suppression of Kiss1-encoded kisspeptin has been suggested to contribute to OIH, the molecular mechanisms for such repression in obesity, and the therapeutic implications thereof, remain unknown. METHODS: A combination of bioinformatic, expression and functional analyses was implemented, assessing the role of the evolutionary-conserved miRNAs, miR-137 and miR-325, in mediating obesity-induced suppression of hypothalamic kisspeptin, as putative mechanism of central hypogonadism and metabolic comorbidities...
May 8, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38677663/statin-treatment-reduces-leucine-turnover-but-does-not-affect-endogenous-production-of-beta-hydroxy-beta-methylbutyrate-hmb
#23
JOURNAL ARTICLE
Martin Hagve, Suzette L Pereira, Dillon K Walker, Marielle P K J Engelen, Nicolaas E P Deutz
BACKGROUND: Statins, or hydroxy-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors, are one of the most commonly prescribed medications for lowering cholesterol. Myopathic side-effects ranging from pain and soreness to critical rhabdomyolysis are commonly reported and often lead to discontinuation. The pathophysiological mechanism is, in general, ascribed to a downstream reduction of Coenzyme Q10 synthesis, resulting in mitochondrial dysfunction. HMG-CoA is a metabolite of leucine and its corresponding keto acid α-ketoisocaproic acid (KIC) and beta-hydroxy-beta-methylbutyrate (HMB), however little is known about the changes in the metabolism of leucine and its metabolites in response to statins...
April 25, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38653373/obesity-and-dyslipidemia-in-early-life-impact-on-cardiometabolic-risk
#24
REVIEW
Aleksandra Zeljkovic, Jelena Vekic, Aleksandra Stefanovic
Childhood obesity with its growing prevalence worldwide presents one of the most important health challenges nowadays. Multiple mechanisms are involved in the development of this condition, as well as in its associations with various cardiometabolic complications, such as insulin resistance, diabetes, metabolic dysfunction-associated steatotic liver disease and cardiovascular diseases. Recent findings suggest that childhood obesity and associated dyslipidemia at least partly originate from epigenetic modifications that take place in the earliest periods of life, namely prenatal and perinatal periods...
April 21, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38643686/corrigendum-to-fundc1-insufficiency-sensitizes-high-fat-diet-intake-induced-cardiac-remodeling-and-contractile-anomaly-through-acsl4-mediated-ferroptosis-metabolism-122-september-2021-154840
#25
Zhaohui Pei, Yandong Liu, Suqin Liu, Wei Jin, Yuanfei Luo, Mingming Sun, Yu Duan, Amir Ajoolabady, James R Sowers, Yan Fang, Feng Cao, Haixia Xu, Yaguang Bi, Shuyi Wang, Jun Ren
No abstract text is available yet for this article.
April 20, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38642829/o-glcnacylation-promotes-the-progression-of-nonalcoholic-fatty-liver-disease-by-upregulating-the-expression-and-function-of-cd36
#26
JOURNAL ARTICLE
Hanlong Zhu, Tianming Zhao, Si Zhao, Suzhen Yang, Kang Jiang, Shupei Li, Ying Kang, Zhuoxin Yang, Jiajia Shen, Si Shen, Hui Tao, Ji Xuan, Miaofang Yang, Bing Xu, Fangyu Wang, Mingzuo Jiang
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) and its progressive variant, nonalcoholic steatohepatitis (NASH), constitute a burgeoning worldwide epidemic with no FDA-approved pharmacotherapies. The multifunctional immunometabolic receptor, fatty acid translocase CD36 (CD36), plays an important role in the progression of hepatic steatosis. O-GlcNAcylation is a crucial posttranslational modification that mediates the distribution and function of CD36, but its involvement in NAFLD remains poorly understood...
April 18, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38642828/virus-induced-diabetes-mellitus-revisiting-infection-etiology-in-light-of-sars-cov-2
#27
REVIEW
Sundararaj Stanleyraj Jeremiah, Abu Saleh Md Moin, Alexandra E Butler
Diabetes mellitus (DM) is comprised of two predominant subtypes: type 1 diabetes mellitus (T1DM), accounting for approximately 5 % of cases worldwide and resulting from autoimmune destruction of insulin-producing β-cells, and type 2 (T2DM), accounting for approximately 95 % of cases globally and characterized by the inability of pancreatic β-cells to meet the demand for insulin due to a relative β-cell deficit in the setting of peripheral insulin resistance. Both types of DM involve derangement of glucose metabolism and are metabolic diseases generally considered to be initiated by a combination of genetic and environmental factors...
April 18, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38599278/baseline-phenotypes-with-preserved-%C3%AE-cell-function-and-high-insulin-concentrations-have-the-best-improvements-in-glucose-tolerance-after-weight-loss-results-from-the-prospective-dexlife-and-egir-risc-studies
#28
RANDOMIZED CONTROLLED TRIAL
Silvia Sabatini, John J Nolan, Grainne O'Donoghue, Aileen Kennedy, John Petrie, Mark Walker, Donal J O'Gorman, Amalia Gastaldelli
BACKGROUND: Weight loss and lifestyle intervention improve glucose tolerance delaying the onset of type 2 diabetes (T2D), but individual responses are highly variable. Determining the predictive factors linked to the beneficial effects of weight loss on glucose tolerance could provide tools for individualized prevention plans. Thus, the aim was to investigate the relationship between pre-intervention values of insulin sensitivity and secretion and the improvement in glucose metabolism after weight loss...
June 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38508373/resmetirom-the-first-approved-drug-for-the-management-of-metabolic-dysfunction-associated-steatohepatitis-trials-opportunities-and-challenges
#29
EDITORIAL
Michail Kokkorakis, Chrysoula Boutari, Michael A Hill, Vasilios Kotsis, Rohit Loomba, Arun J Sanyal, Christos S Mantzoros
No abstract text is available yet for this article.
May 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38631460/glucagon-augments-the-secretion-of-fgf21-and-gdf15-in-masld-by-indirect-mechanisms
#30
JOURNAL ARTICLE
Michael M Richter, Ida M Kemp, Sara Heebøll, Marie Winther-Sørensen, Sasha A S Kjeldsen, Nicole J Jensen, Janus D Nybing, Frederik H Linden, Erik Høgh-Schmidt, Mikael P Boesen, Sten Madsbad, Frank Vinholt Schiødt, Kirsten Nørgaard, Signe Schmidt, Lise Lotte Gluud, Steen B Haugaard, Jens J Holst, Søren Nielsen, Jørgen Rungby, Nicolai J Wewer Albrechtsen
INTRODUCTION: Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be mediated by increases in circulating levels of Fibroblast Growth Factor 21 (FGF21) and Growth Differentiation Factor 15 (GDF15). The effect of glucagon agonism on FGF21 and GDF15 levels remains uncertain, especially in the context of elevated insulin levels commonly observed in metabolic diseases...
April 15, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38622040/corrigendum-to-imeglimin-improves-systemic-metabolism-by-targeting-brown-adipose-tissue-and-gut-microbiota-in-obese-model-mice-metabolism-153-april-2024-155796
#31
Motoharu Awazawa, Maya Matsushita, Ikumi Nomura, Naoki Kobayashi, Miwa Tamura-Nakano, Yuriko Sorimachi, Keiyo Takubo, Kohjiro Ueki
No abstract text is available yet for this article.
April 15, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38615945/hepatic-klf10-fh1-axis-promotes-exercise-mediated-amelioration-of-nash-in-mice
#32
JOURNAL ARTICLE
Hong-Yang Luo, Wang-Jing Mu, Min Chen, Jie-Ying Zhu, Yang Li, Shan Li, Lin-Jing Yan, Ruo-Ying Li, Meng-Ting Yin, Xin Li, Hu-Min Chen, Liang Guo
Exercise is an effective non-pharmacological strategy for the treatment of nonalcoholic steatohepatitis (NASH), but the underlying mechanism needs further investigation. Kruppel-like factor 10 (Klf10) is a transcriptional factor that is expressed in multiple tissues including liver, whose role in NASH is not well defined. In our study, exercise induces hepatic Klf10 expression through the cAMP/PKA/CREB pathway. Hepatocyte-specific knockout of Klf10 (Klf10LKO ) increases lipid accumulation, cell death, inflammation and fibrosis in NASH diet-fed mice and reduces the protective effects of treadmill exercise against NASH, while hepatocyte-specific overexpression of Klf10 (Klf10LTG ) works in concert with exercise to reduce NASH in mice...
April 12, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609039/role-of-mitochondria-in-pathogenesis-and-therapy-of-renal-fibrosis
#33
REVIEW
Xiaodong Zhao, Yunkuo Li, Jinyu Yu, Haolin Teng, Shouwang Wu, Yishu Wang, Honglan Zhou, Faping Li
Renal fibrosis, specifically tubulointerstitial fibrosis, represents the predominant pathological consequence observed in the context of progressive chronic kidney conditions. The pathogenesis of renal fibrosis encompasses a multifaceted interplay of mechanisms, including but not limited to interstitial fibroblast proliferation, activation, augmented production of extracellular matrix (ECM) components, and impaired ECM degradation. Notably, mitochondria, the intracellular organelles responsible for orchestrating biological oxidation processes in mammalian cells, assume a pivotal role within this intricate milieu...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609038/deciphering-the-molecular-pathways-of-saroglitazar-a-dual-ppar-%C3%AE-%C3%AE-agonist-for-managing-metabolic-nafld
#34
REVIEW
Devaraj Ezhilarasan
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist, has been used to treat metabolic diseases such as insulin resistance and diabetic dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD). SARO, administered at a dose of 4 mg/day, has been consistently studied in clinical trials with different time points ranging from 4 to 24 weeks with NAFLD patients. Due to its PPAR-γ agonistic action, SARO prevents adipose tissue-mediated fatty acid delivery to the liver by increasing insulin sensitivity and regulating adiponectin and leptin levels in adipose tissue...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38609037/myeloid-trem2-ameliorates-the-progression-of-metabolic-dysfunction-associated-steatotic-liver-disease-by-regulating-macrophage-pyroptosis-and-inflammation-resolution
#35
JOURNAL ARTICLE
Wenjie Yu, Yu Zhang, Linfeng Sun, Wei Huang, Xiangdong Li, Nan Xia, Xuejiao Chen, Likalamu Pascalia Wikana, Yuhao Xiao, Minhao Chen, Sheng Han, Ziyi Wang, Liyong Pu
BACKGROUND: The prevalence of Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing year by year and has become one of the leading causes of end-stage liver disease worldwide. Triggering Receptor Expressed on Myeloid Cells 2 (Trem2) has been confirmed to play an essential role in the progression of MASLD, but its specific mechanism still needs to be clarified. This study aims to explore the role and mechanism of Trem2 in MASLD. METHODS: Human liver tissues were obtained from patients with MASLD and controls...
April 10, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38582490/kr%C3%A3-ppel-like-factor-10-protects-against-metabolic-dysfunction-associated-steatohepatitis-by-regulating-hnf4%C3%AE-mediated-metabolic-pathways
#36
JOURNAL ARTICLE
Xiaoli Pan, Shuwei Hu, Yanyong Xu, Raja Gopoju, Yingdong Zhu, Fathima N Cassim Bawa, Hui Wang, Jiayou Wang, Zaid Batayneh, Alyssa Clark, Yuhao Zeng, Li Lin, Xinwen Wang, Liya Yin, Yanqiao Zhang
BACKGROUND: Krüppel-like factor 10 (KLF10), a zinc finger transcription factor, plays a pivotal role in modulating TGF-β-mediated cellular processes such as growth, apoptosis, and differentiation. Recent studies have implicated KLF10 in regulating lipid metabolism and glucose homeostasis. This study aimed to elucidate the precise role of hepatic KLF10 in developing metabolic dysfunction-associated steatohepatitis (MASH) in diet-induced obese mice. METHODS: We investigated hepatic KLF10 expression under metabolic stress and the effects of overexpression or ablation of hepatic KLF10 on MASH development and lipidemia...
April 4, 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38307325/intermittent-fasting-protects-%C3%AE-cell-identity-and-function-in-a-type-2-diabetes-model
#37
JOURNAL ARTICLE
Sumit Patel, Zihan Yan, Maria S Remedi
Type 2 diabetes (T2DM) is caused by the interaction of multiple genes and environmental factors. T2DM is characterized by hyperglycemia, insulin secretion deficiency and insulin resistance. Chronic hyperglycemia induces β-cell dysfunction, loss of β-cell mass/identity and β-cell dedifferentiation. Intermittent fasting (IF) a commonly used dietary regimen for weight-loss, also induces metabolic benefits including reduced blood glucose, improved insulin sensitivity, reduced adiposity, inflammation, oxidative-stress and increased fatty-acid oxidation; however, the mechanisms underlying these effects in pancreatic β-cells remain elusive...
April 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38301843/identification-of-mgmt-promoter-methylation-as-a-specific-lipid-metabolism-biomarker-reveals-the-feasibility-of-atorvastatin-application-in-glioblastoma
#38
JOURNAL ARTICLE
Zhaonian Hao, Jiejun Wang, Yifan Lv, Weiqi Wu, Shaodong Zhang, Shuyu Hao, Junsheng Chu, Hong Wan, Jie Feng, Nan Ji
BACKGROUND: Glioblastoma is one of the deadliest tumors, and limited improvement in managing glioblastoma has been achieved in the past decades. The unmethylated promoter area of 6-O-Methylguanine-DNA Methyltransferase (MGMT) is a significant biomarker for recognizing a subset of glioblastoma that is resistant to chemotherapy. Here we identified MGMT methylation can also work as a specific biomarker to classify the lipid metabolism patterns between methylated and unmethylated glioblastoma and verify the potential novel therapeutic strategy for unmethylated MGMT glioblastoma...
April 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38262576/imeglimin-improves-systemic-metabolism-by-targeting-brown-adipose-tissue-and-gut-microbiota-in-obese-model-mice
#39
JOURNAL ARTICLE
Motoharu Awazawa, Maya Matsushita, Ikumi Nomura, Naoki Kobayashi, Miwa Tamura-Nakano, Yuriko Sorimachi, Keiyo Takubo, Kohjiro Ueki
Imeglimin is a recently developed anti-diabetic drug that could concurrently promote insulin secretion and insulin sensitivity, while its mechanisms of action are not fully understood. Here we show that imeglimin administration could protect mice from high fat diet-induced weight gain with enhanced energy expenditure and attenuated whitening of brown adipose tissue. Imeglimin administration led to significant alteration of gut microbiota, which included an increase of Akkermansia genus, with attenuation of obesity-associated gut pathologies...
April 2024: Metabolism: Clinical and Experimental
https://read.qxmd.com/read/38232802/effect-of-sodium-glucose-cotransporter-2-inhibitors-on-continuous-glucose-monitoring-metrics-as-adjunctive-to-insulin-in-adults-with-type-1-diabetes-mellitus-a-meta-analysis-of-randomized-controlled-trials
#40
JOURNAL ARTICLE
Djordje S Popovic, Paschalis Karakasis, Theocharis Koufakis, Nikolaos Fragakis, Nikolaos Papanas, Milena Mitrovic, Evanthia Gouveri, Dimitrios Patoulias
AIMS: This meta-analysis of randomized controlled trials (RCTs) aimed to evaluate the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on continuous glucose monitoring metrics as adjunctive to insulin in adults with type 1 diabetes mellitus (T1D). METHODS: A systematic literature search was conducted through Medline (via PubMed), Cochrane Library and Google Scholar until October 25, 2023. Dual-independent study selection, data extraction and quality assessment were conducted...
April 2024: Metabolism: Clinical and Experimental
journal
journal
23785
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.